ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: GlaxoSmithKline plc Sponsored ADR (GSK) Report Updated: Nov 24, 2014 | Print This Page

GlaxoSmithKline plc Sponsored ADR© quotemedia

Company Profile

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, HIV, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, vaccines, and dermatologicals. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets a range of vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company provides OTC medicines, including Panadol, a paracetamol-based treatment of headache and joint pain, fever, and cold symptoms; Gaviscon, a range of antacid products that relieve heartburn due to acid reflux; and NicoDerm, NiQuitin CQ, Nicabate, and Nicorette for the treatment of nicotine withdrawal as an aid to quit smoking. Further, it offers oral healthcare products comprising Sensodyne, a range of toothpastes and toothbrushes; Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; and Polident, Poligrip, and Corega, which are denture adhesives and cleansers. Additionally, the company provides nutritional healthcare products consisting of Lucozade, an energy and sports drinks; Horlicks, a malted, milk-based drink and food; and Ribena, an apple, orange, raspberry, and pomegranate flavored fruit drink, as well as markets skincare products. It has drug discovery research collaboration with Yale University to design various medicines that degrade disease-causing proteins. The company was incorporated in 1999 and is headquartered in Brentford, United Kingdom.

Recent News: GlaxoSmithKline plc Sponsored ADR